Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Advances in Pharmacokinetics, Pharmacodynamics and Drug Interactions, 2nd Edition
share announcement

Advances in Pharmacokinetics, Pharmacodynamics and Drug Interactions, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 2830

Special Issue Editors

Dr. Kyeong-Ryoon Lee

E-Mail Website
Guest Editor
Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology, Cheongju 28116, Republic of Korea
Interests: pharmacokinetics; physiologically based pharmacokinetic (PBPK) modeling and simulation; pharmacokinetic–pharmacodynamic (PK-PD) modeling and simulation; drug–drug interaction (DDI); in vitro–in vivo extrapolation (IVIVE)
Special Issues, Collections and Topics in MDPI journals
Dr. Yoon-Jee Chae

E-Mail Website
Guest Editor
College of Pharmacy, Woosuk University, Wanju-gun 55338, Republic of Korea
Interests: pharmacokinetics; drug interactions; transrpoters; CYP450 induction; pharmacokinetic alteractions in disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleague,

Pharmacokinetics and pharmacodynamics are important evaluation steps for understanding the behavior of drugs and their efficacy after administration in drug development. Drug interaction studies are also essential in drug development, and aid in the preparation of drug development strategies in clinical studies. In conventional studies, pharmacokinetics, pharmacodynamics and drug interactions have been considered as purely analytical tools, but these days they are applied to predict drug properties in inter-species studies, including in humans, along with model-based approaches. These research studies have increased in number, leading to new technologies or platforms being introduced; therefore, it is expected that various research outputs will be reported.

We invite research scientists who study pharmacokinetics, pharmacodynamics and drug interactions to submit original research articles, review articles or commentaries. This Special Issue will provide researchers with information and an up-to-date resource.

Dr. Kyeong-Ryoon Lee
Dr. Yoon-Jee Chae
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacokinetics
  • pharmacodynamics
  • PK/PD modeling
  • drug–drug interactions
  • PBPK model
  • drug delivery
  • drug development

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 239 KiB  
Article
Drug–Drug Interactions in Patients with Acute Respiratory Distress Syndrome
by Thorsten Bischof, Christoph Schaller, Nina Buchtele, Thomas Staudinger, Roman Ullrich, Felix Kraft, Marine L. Andersson, Bernd Jilma and Christian Schoergenhofer
Pharmaceutics 2024, 16(3), 303; https://doi.org/10.3390/pharmaceutics16030303 - 21 Feb 2024
Viewed by 678
Abstract
Acute respiratory distress syndrome (ARDS) is a potential life-threatening, heterogenous, inflammatory lung disease. There are no data available on potential drug–drug interactions (pDDIs) in critically ill patients with ARDS. This study analyzed pDDIs in this specific cohort and aimed to investigate possible associations [...] Read more.
Acute respiratory distress syndrome (ARDS) is a potential life-threatening, heterogenous, inflammatory lung disease. There are no data available on potential drug–drug interactions (pDDIs) in critically ill patients with ARDS. This study analyzed pDDIs in this specific cohort and aimed to investigate possible associations of coronavirus disease 2019 (COVID-19) as an underlying cause of ARDS and treatment with extracorporeal membrane oxygenation (ECMO) with the occurrence of pDDIs. This retrospective study included patients ≥18 years of age diagnosed with ARDS between January 2010 and September 2021. The Janusmed database was used for the identification of pDDIs. A total of 2694 pDDIs were identified in 189 patients with a median treatment duration of 22 days. These included 323 (12%) clinically relevant drug combinations that are best avoided, corresponding to a median rate of 0.05 per day. There was no difference in the number of pDDIs between COVID-19- and non-COVID-19-associated ARDS. In patients treated with ECMO, the rate of the most severely graded pDDIs per day was significantly higher compared with those who did not require ECMO. PDDIs occur frequently in patients with ARDS. On average, each patient may encounter at least one clinically relevant drug combination that should be avoided during their intensive care unit stay. Full article
(This article belongs to the Special Issue Advances in Pharmacokinetics, Pharmacodynamics and Drug Interactions, 2nd Edition)
8 pages, 753 KiB  
Communication
Influence of Intramuscular Injection Sites on Pharmacokinetics of Amoxicillin in Olive Flounder (Paralichthys olivaceus) and Its Implication for Antibacterial Efficacy
by Ji-Hoon Lee, Ga-Won Kim, Hyun-Woo Kang, Joo-Won Hong, Hyo-Eun Lee, Mun-Gyeong Kwon and Jung-Soo Seo
Pharmaceutics 2023, 15(4), 1153; https://doi.org/10.3390/pharmaceutics15041153 - 05 Apr 2023
Viewed by 1440
Abstract
This study aimed to investigate the effects of different injection sites, including dorsal, cheek, and pectoral fin muscles, on the pharmacological properties of amoxicillin (AMOX) in olive flounder (Paralichthys olivaceus) after a single intramuscular (IM) injection of 40 mg/kg. The AMOX [...] Read more.
This study aimed to investigate the effects of different injection sites, including dorsal, cheek, and pectoral fin muscles, on the pharmacological properties of amoxicillin (AMOX) in olive flounder (Paralichthys olivaceus) after a single intramuscular (IM) injection of 40 mg/kg. The AMOX concentration was measured using high-performance liquid chromatography-tandem mass spectrometry, followed by a non-compartmental model analysis. The peak serum concentrations (Cmax) achieved 3 h after dorsal, cheek, and pectoral fin IM injections were 202.79, 203.96, and 229.59 μg/mL, respectively. The area under the concentration-time curve (AUC) was 1697.23, 2006.71, and 1846.61 µg/mL·h, respectively. The terminal half-life (t1/2λZ) was prolonged for cheek and pectoral fin IM injections (10.12 and 10.33 h, respectively) compared to dorsal IM injection (8.89 h). In the pharmacokinetic-pharmacodynamic analysis, a higher T > minimum inhibitory concentration (MIC) and AUC/MIC values were observed after AMOX was injected into the cheek and pectoral fin muscles compared to the dorsal muscle. Muscle residue depletion was below the maximum residue level from day 7 after IM injection at all three sites. These findings suggest that the cheek and pectoral fin sites provide advantages regarding systemic drug exposure and prolonged action compared with the dorsal site. Full article
(This article belongs to the Special Issue Advances in Pharmacokinetics, Pharmacodynamics and Drug Interactions, 2nd Edition)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop